Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy

NCT02894398 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT02894398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02894398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy
Lead sponsor
iOMEDICO AG
Phase
Phase 2
Overall status
Completed
Start date
September 6, 2016
Completion date
February 15, 2023
Enrollment
388 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor positive tumor, human epidermal growth factor 2 negative carcinoma of breast